[{"data":1,"prerenderedAt":26},["ShallowReactive",2],{"$f1fwJCTFQyRCtFT8s1_TzQgI3prtJAXy4631LB-RXy-0":3},{"card":4,"examId":6,"chapterTitle":23,"prev":24,"next":25},{"id":5,"examId":6,"prompt":7,"answer":8,"choices":9,"questionType":14,"explanation":15,"explanationDetail":16,"mistakeHint":17,"lectureRef":16,"storyRef":16,"chapterSlug":18,"sectionCode":19,"sectionTitle":20,"clusterSlug":21,"term":16,"sequenceOrder":16,"regionWeight":16,"revisionMark":16,"isActive":22},"ch5-036","touhan","医薬品・医療機器等安全性情報報告制度の報告書の提出先として正しいのはどれか。",2,[10,11,12,13],"都道府県知事","厚生労働大臣（直接）","総合機構","保健所長","four","実務上は法第68条の13第3項の規定により、報告書を総合機構（PMDA）に提出することとされています。",null,"法律上の報告先は厚生労働大臣ですが、実務上の提出先は総合機構（PMDA）です。この違いは試験でよく問われます。","chapter-5","5-II-1","副作用情報等の収集","fukusayou-shuushuu",true,"第5章 医薬品の適正使用・安全対策","ch5-035","ch5-037",1784619074264]